Compare · TCRR vs TMPM
TCRR vs TMPM
Side-by-side comparison of TCR2 Therapeutics Inc. (TCRR) and Turmeric Acquisition Corp. (TMPM): market cap, price performance, sector, and recent activity on the wire.
Summary
- TCRR operates in Health Care, while TMPM operates in Finance - the two are in different parts of the market.
- TMPM is the larger of the two at $123.9M, about the same size as TCRR ($123.1M).
- TCRR has more recent analyst coverage (10 ratings vs 0 for TMPM).
- Company
- TCR2 Therapeutics Inc.
- Turmeric Acquisition Corp.
- Price
- $1.52-3.49%
- $10.01+0.00%
- Market cap
- $123.1M
- $123.9M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Business Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 0
- 0
- Recent ratings
- 10
- 0
TCR2 Therapeutics Inc.
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies, including adult acute lymphoblastic leukemia, DLBCL, follicular lymphoma, and other non-hodgkin lymphomas that is in phase I/II clinical trial. It is also developing TC-510 for, GPC3, IL-15, and Allogenic for solid tumors, as well as DC70 for solid tumors and hematological malignancies. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Turmeric Acquisition Corp.
Turmeric Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2020 and is headquartered in Cambridge, Massachusetts. Turmeric Acquisition Corp. operates as a subsidiary of Turmeric Management, LLC.
Latest TCRR
- Tang Kevin C disposed of 4,394,800 shares (SEC Form 4)
- SEC Form SC 13G/A filed by TCR2 Therapeutics Inc. (Amendment)
- SEC Form 15-12G filed by TCR2 Therapeutics Inc.
- SEC Form EFFECT filed by TCR2 Therapeutics Inc.
- SEC Form EFFECT filed by TCR2 Therapeutics Inc.
- SEC Form EFFECT filed by TCR2 Therapeutics Inc.
- SEC Form 4 filed by Ubs Oncology Impact Fund L.P.
- SEC Form 4 filed by Mpm Sunstates Fund, L.P.
- SEC Form 4 filed by Mpm Bioventures 2014, L.P.
- SEC Form 4 filed by Gadicke Ansbert
Latest TMPM
- SEC Form SC 13G/A filed by Turmeric Acquisition Corp. (Amendment)
- SEC Form SC 13G/A filed by Turmeric Acquisition Corp. (Amendment)
- SEC Form 15-12G filed by Turmeric Acquisition Corp.
- SEC Form 25-NSE filed by Turmeric Acquisition Corp.
- Turmeric Acquisition Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Turmeric Acquisition Corp. Will Redeem Its Public Shares And Will Not Consummate An Initial Business Combination
- Turmeric Acquisition Corp. Will Redeem Its Public Shares and Will Not Consummate an Initial Business Combination
- SEC Form PRE 14A filed by Turmeric Acquisition Corp.
- SEC Form 10-K/A filed by Turmeric Acquisition Corp. (Amendment)
- Turmeric Acquisition Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing